Clinical Trial Update: Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS). [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial (TRECOS) comparing CHF5993 inhalation with HFA-152a versus HFA-134a as pMDIs in subjects with asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• CHF5993 HFA-134a pMDI (CHF5993)
• CHF5993 HFA-152a pMDI (CHF5993)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Asthma | Phase 3 | Status: COMPLETED